These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 34046846)

  • 21. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
    Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical burden of relapses in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: A single center cohort analysis.
    Kadish R; Clardy SL; Royston M; Tanvir I; Parker T; Biskupiak J; Kielhorn A
    J Neuroimmunol; 2022 Jan; 362():577761. PubMed ID: 34823121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder.
    Shi B; Zhao M; Qiao L; Huang F; Zhou S; Wei Y; Wang J; Wang N
    Mult Scler Relat Disord; 2021 Sep; 54():103143. PubMed ID: 34273608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinally Extensive Transverse Myelitis: A Retrospective Study Differentiating Neuromyelitis Optica Spectrum Disorder From Other Etiologies.
    Paudel S; Nepal G; Guragain S; Shah S; Paudel BS; Ojha R; Rajbhandari R; Karn R; Gajurel BP; Paudel S
    Cureus; 2021 Mar; 13(3):e13968. PubMed ID: 33884229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
    Takai Y; Kuroda H; Misu T; Akaishi T; Nakashima I; Takahashi T; Nishiyama S; Fujihara K; Aoki M
    Mult Scler Relat Disord; 2021 Apr; 49():102750. PubMed ID: 33524925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder.
    Liu YH; Guo YC; Lin LY; Tsai CP; Fuh JL; Wang YF; Chen SP; Wu HM; Yu KW; Lin KP; Wang SJ; Liao YC; Lee YC
    J Formos Med Assoc; 2022 Sep; 121(9):1647-1656. PubMed ID: 34802834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relatively Early and Late-Onset Neuromyelitis Optica Spectrum Disorder in Central China: Clinical Characteristics and Prognostic Features.
    Yu J; Yan S; Niu P; Teng J
    Front Neurol; 2022; 13():859276. PubMed ID: 35493805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.
    Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K
    Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
    J Tullman M; Zabeti A; Vuocolo S; Dinh Q
    Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuromyelitis Optica Spectrum Disorder: Disease Course and Long-Term Visual Outcome.
    Brody J; Hellmann MA; Marignier R; Lotan I; Stiebel-Kalish H
    J Neuroophthalmol; 2016 Dec; 36(4):356-362. PubMed ID: 27348750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and Radiological Characteristics of Neuromyelitis Optica Spectrum Disorder: The Experience from Saudi Arabia.
    Algahtani H; Shirah B; Ibrahim B; Malik YA; Makkawi S
    Mult Scler Relat Disord; 2021 Jan; 47():102668. PubMed ID: 33307475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.
    Fujihara K; Bennett JL; de Seze J; Haramura M; Kleiter I; Weinshenker BG; Kang D; Mughal T; Yamamura T
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32820020
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.